New small molecule entry inhibitors targeting hemagglutinin-mediated influenza A virus fusion

Journal of Virology

Volumn 88, Issue 3, 2014, Pages 1447-1460

  Basu, Arnab ^a   Antanasijevic, Aleksandar ^b   Wang, Minxiu ^c   Li, Bing ^a   Mills, Debra M ^a   Ames, Jessica A ^a   Nash, Peter J ^a   Williams, John D ^a   Peet, Norton P ^a   Moir, Donald T ^a   Prichard, Mark N ^d   Keith, Kathy A ^d   Barnard, Dale L ^e   Caffrey, Michael ^b   Rong, Lijun ^c   Bowlin, Terry L ^a  

^a MICROBIOTIX INC   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

^d UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^e UTAH STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; INFLUENZA VIRUS HEMAGGLUTININ; MBX 2329; MBX 2546; OSELTAMIVIR; SULFONAMIDE; UNCLASSIFIED DRUG;

2009 H1N1 INFLUENZA; ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; AVIAN INFLUENZA VIRUS; CHICKEN; CONTROLLED STUDY; CYTOTOXICITY CONCENTRATION 50; CYTOTOXICITY TEST; DRUG POTENCY; DRUG POTENTIATION; DRUG SCREENING; DRUG STRUCTURE; ERYTHROCYTE; HEMOLYSIS; HIGH THROUGHPUT SCREENING; IC 50; INFLUENZA A (H5N1); INFLUENZA VIRUS A; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; MEMBRANE FUSION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RECEPTOR BINDING; VIRUS ENTRY; VIRUS STRAIN;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CHICKENS; HEMAGGLUTININS, VIRAL; HUMANS; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA IN BIRDS; INFLUENZA, HUMAN; POULTRY DISEASES; SMALL MOLECULE LIBRARIES; VIRUS INTERNALIZATION;

EID: 84892471469     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01225-13     Document Type: Article

References (63)

1. Russell CJ, Webster RG. 2005. The genesis of a pandemic influenza virus. Cell 123:368-371. http://dx.doi.org/10.1016/j.cell.2005.10.019.
2. Tscherne DM, Garcia-Sastre A. 2011. Virulence determinants of pandemic influenza viruses. J. Clin. Invest. 121:6-13. http://dx.doi.org/10 .1172/JCI44947.
3. Yen HL, Webster RG. 2009. Pandemic influenza as a current threat. Curr. Top. Microbiol. Immunol. 333:3-24. http://dx.doi.org/10.1007/978-3-540-92165-3_1.
4. Brockwell-Staats C, Webster RG, Webby RJ. 2009. Diversity of influenza viruses in swine and the emergence of a novel human pandemic influenza A(H1N1). Influenza Other Respi. Viruses 3:207-213. http://dx.doi.org/10 .1111/j.1750-2659.2009.00096.x.
5. Horimoto T, Kawaoka Y. 2009. Designing vaccines for pandemic influenza. Curr. Top. Microbiol. Immunol. 333:165-176. http://dx.doi.org/10 .1007/978-3-540-92165-3_8.
6. Smith GJ, Bahl J, Vijaykrishna D, Zhang J, Poon LL, Chen H, Webster RG, Peiris JS, Guan Y. 2009. Dating the emergence of pandemic influenza viruses. Proc. Natl. Acad. Sci. U.S.A. 106:11709-11712. http://dx.doi.org/10.1073/pnas.0904991106.
7. Das K, Aramini JM, Ma LC, Krug RM, Arnold E. 2010. Structures of influenza A proteins and insights into antiviral drug targets. Nat. Struct. Mol. Biol. 17:530-538. http://dx.doi.org/10.1038/nsmb.1779.
8. De Clercq E. 2006. Antiviral agents active against influenza A viruses. Nat. Rev. Drug Discov. 5:1015-1025. http://dx.doi.org/10.1038/nrd2175.
9. De Clercq E, Neyts J. 2007. Avian influenza A (H5N1) infection: targets and strategies for chemotherapeutic intervention. Trends Pharmacol. Sci. 28:280-285. http://dx.doi.org/10.1016/j.tips.2007.04.005.
10. van der Vries E, Stelma FF, Boucher CA. 2010. Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. N. Engl. J. Med. 363: 1381-1382. http://dx.doi.org/10.1056/NEJMc1003749.
11. Skehel J. 2009. An overview of influenza haemagglutinin and neuraminidase. Biologicals 37:177-178. http://dx.doi.org/10.1016/j.biologicals .2009.02.012.
12. Baz M, Abed Y, Simon P, Hamelin ME, Boivin G. 2010. Effect of the neuraminidase mutation H274Y conferring resistance to oseltamivir on the replicative capacity and virulence of old and recent human influenza A(H1N1) viruses. J. Infect. Dis. 201:740-745. http://dx.doi.org/10.1086/650464.
13. Lackenby A, Democratis J, Siqueira MM, Zambon MC. 2008. Rapid quantitation of neuraminidase inhibitor drug resistance in influenza virus quasispecies. Antivir. Ther. 13:809-820. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18445375.
14. Lackenby A, Hungnes O, Dudman SG, Meijer A, Paget WJ, Hay AJ, Zambon MC. 2008. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro Surveill. 13(5):pii=8026. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=8026.
15. Lackenby A, Thompson CI, Democratis J. 2008. The potential impact of neuraminidase inhibitor resistant influenza. Curr. Opin. Infect. Dis. 21: 626-638. http://dx.doi.org/10.1097/QCO.0b013e3283199797.
16. Le QM, Kiso M, Someya K, Sakai YT, Nguyen TH, Nguyen KH, Pham ND, Ngyen HH, Yamada S, Muramoto Y, Horimoto T, Takada A, Goto H, Suzuki T, Suzuki Y, Kawaoka Y. 2005. Avian flu: isolation of drug-resistant H5N1 virus. Nature 437:1108. http://dx.doi .org/10.1038/4371108a.
17. Chen LF, Dailey NJ, Rao AK, Fleischauer AT, Greenwald I, Deyde VM, Moore ZS, Anderson DJ, Duffy J, Gubareva LV, Sexton DJ, Fry AM, Srinivasan A, Wolfe CR. 2011. Cluster of oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infections on a hospital ward among immunocompromised patients-North Carolina, 2009. J. Infect. Dis. 203:838-846. http://dx.doi.org/10.1093/infdis/jiq124.
18. Mehta T, McGrath E, Bheemreddy S, Salimnia H, Abdel-Haq N, Ang JY, Lum L, Chandrasekar P, Alangaden GJ. 2010. Detection of oseltamivir resistance during treatment of 2009 H1N1 influenza virus infection in immunocompromised patients: utility of cycle threshold values of qual-itative real-time reverse transcriptase PCR. J. Clin. Microbiol. 48:4326-4328. http://dx.doi.org/10.1128/JCM.01190-10.
19. Sheu TG, Deyde VM, Garten RJ, Klimov AI, Gubareva LV. 2010. Detection of antiviral resistance and genetic lineage markers in influenza B virus neuraminidase using pyrosequencing. Antiviral Res. 85:354-360. http://dx.doi.org/10.1016/j.antiviral.2009.10.022.
20. Moss RB, Davey RT, Steigbigel RT, Fang F. 2010. Targeting pandemic influenza: a primer on influenza antivirals and drug resistance. J. Antimicrob. Chemother. 65:1086-1093. http://dx.doi.org/10.1093/jac/dkq100.
21. Sambhara S, Poland GA. 2010. H5N1 avian influenza: preventive and therapeutic strategies against a pandemic. Annu. Rev. Med. 61:187-198. http://dx.doi.org/10.1146/annurev.med.050908.132031.
22. Oldstone MB, Teijaro JR, Walsh KB, Rosen H. 2013. Dissecting influenza virus pathogenesis uncovers a novel chemical approach to combat the infection. Virology 435:92-101. http://dx.doi.org/10.1016/j.virol.2012 .09.039.
23. Skehel JJ, Wiley DC. 2000. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu. Rev. Biochem. 69:531-569. http://dx.doi.org/10.1146/annurev.biochem.69.1.531.
24. Guo Y, Rumschlag-Booms E, Wang J, Xiao H, Yu J, Wang J, Guo L, Gao GF, Cao Y, Caffrey M, Rong L. 2009. Analysis of hemagglutininmediated entry tropism of H5N1 avian influenza. Virol. J. 6:39. http://dx .doi.org/10.1186/1743-422X-6-39.
25. Manicassamy B, Wang J, Jiang H, Rong L. 2005. Comprehensive analysis of Ebola virus GP1 in viral entry. J. Virol. 79:4793-4805. http://dx.doi.org/10.1128/JVI.79.8.4793-4805.2005.
26. Basu A, Kanda T, Beyene A, Saito K, Meyer K, Ray R. 2007. Sulfated homologues of heparin inhibit hepatitis C virus entry into mammalian cells. J. Virol. 81:3933-3941. http://dx.doi.org/10.1128/JVI.02622-06.
27. Radoshitzky SR, Abraham J, Spiropoulou CF, Kuhn JH, Nguyen D, Li W, Nagel J, Schmidt PJ, Nunberg JH, Andrews NC, Farzan M, Choe H. 2007. Transferrin receptor 1 is a cellular receptor for New World haemorrhagic fever arenaviruses. Nature 446:92-96. http://dx.doi.org/10.1038/nature05539.
28. Radoshitzky SR, Kuhn JH, Spiropoulou CF, Albariño CG, Nguyen DP, Salazar-Bravo J, Dorfman T, Lee AS, Wang E, Ross SR, Choe H, Farzan M. 2008. Receptor determinants of zoonotic transmission of New World hemorrhagic fever arenaviruses. Proc. Natl. Acad. Sci. U.S.A. 105:2664-2669. http://dx.doi.org/10.1073/pnas.0709254105.
29. Russell CA, Jones TC, Barr IG, Cox NJ, Garten RJ, Gregory V, Gust ID, Hampson AW, Hay AJ, Hurt AC, de Jong JC, Kelso A, Klimov AI, Kageyama T, Komadina N, Lapedes AS, Lin YP, Mosterin A, Obuchi M, Odagiri T, Osterhaus AD, Rimmelzwaan GF, Shaw MW, Skepner E, Stohr K, Tashiro M, Fouchier RA, Smith DJ. 2008. Influenza vaccine strain selection and recent studies on the global migration of seasonal influenza viruses. Vaccine 26(Suppl 4):D31-D34.
30. Rumschlag-Booms E, Guo Y, Wang J, Caffrey M, Rong L. 2009. Comparative analysis between a low pathogenic and a high pathogenic influenza H5 hemagglutinin in cell entry. Virol. J. 6:76. http://dx.doi.org/10 .1186/1743-422X-6-76.
31. Basu A, Li B, Mills DM, Panchal RG, Cardinale SC, Butler MM, Peet NP, Majgier-Baranowska H, Williams JD, Patel I, Moir DT, Bavari S, Ray R, Farzan MR, Rong L, Bowlin TL. 2011. Identification of a smallmolecule entry inhibitor for filoviruses. J. Virol. 85:3106-3119. http://dx .doi.org/10.1128/JVI.01456-10.
32. Zhang JH, Chung TD, Oldenburg KR. 1999. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4:67-73. http://dx.doi.org/10.1177/108705719900400206.
33. Plotch SJ, O'Hara B, Morin J, Palant O, LaRocque J, Bloom JD, Lang SA, Jr, DiGrandi MJ, Bradley M, Nilakantan R, Gluzman Y. 1999. Inhibition of influenza A virus replication by compounds interfering with the fusogenic function of the viral hemagglutinin. J. Virol. 73:140-151.
34. Vanderlinden E, Goktas F, Cesur Z, Froeyen M, Reed ML, Russell CJ, Cesur N, Naesens L. 2010. Novel inhibitors of influenza virus fusion: structure-activity relationship and interaction with the viral hemagglutinin. J. Virol. 84:4277-4288. http://dx.doi.org/10.1128/JVI.02325-09.
35. Wang M, Tscherne DM, McCullough C, Caffrey M, Garcia-Sastre A, Rong L. 2012. Residue Y161 of influenza virus hemagglutinin is involved in viral recognition of sialylated complexes from different hosts. J. Virol. 86:4455-4462. http://dx.doi.org/10.1128/JVI.07187-11.
36. Luo G, Torri A, Harte WE, Danetz S, Cianci C, Tiley L, Day S, Mullaney D, Yu KL, Ouellet C, Dextraze P, Meanwell N, Colonno R, Krystal M. 1997. Molecular mechanism underlying the action of a novel fusion inhibitor of influenza A virus. J. Virol. 71:4062-4070.
37. Dalvit C, Fogliatto G, Stewart A, Veronesi M, Stockman B. 2001. WaterLOGSY as a method for primary NMR screening: practical aspects and range of applicability. J. Biomol. NMR 21:349-359. http://dx.doi.org/10.1023/A:1013302231549.
38. Nomme J, Fanning AS, Caffrey M, Lye MF, Anderson JM, Lavie A. 2011. The Src homology 3 domain is required for junctional adhesion molecule binding to the third PDZ domain of the scaffolding protein ZO-1. J. Biol. Chem. 286:43352-43360. http://dx.doi.org/10.1074/jbc.M111.304089.
39. Celigoy J, Ramirez B, Tao L, Rong L, Yan L, Feng YR, Quinnan GV, Broder CC, Caffrey M. 2011. Probing the HIV gp120 envelope glycoprotein conformation by NMR. J. Biol. Chem. 286:23975-23981. http://dx .doi.org/10.1074/jbc.M111.251025.
40. McCullough C, Wang M, Rong L, Caffrey M. 2012. Characterization of influenza hemagglutinin interactions with receptor by NMR. PLoS One 7:e33958. http://dx.doi.org/10.1371/journal.pone.0033958.
41. Meyer B, Peters T. 2003.NMRspectroscopy techniques for screening and identifying ligand binding to protein receptors. Angew. Chem. Int. Ed. Engl. 42:864-890. http://dx.doi.org/10.1002/anie.200390233.
42. Hakansson-McReynolds S, Jiang S, Rong L, Caffrey M. 2006. Solution structure of the severe acute respiratory syndrome-coronavirus heptad repeat 2 domain in the prefusion state. J. Biol. Chem. 281:11965-11971. http://dx.doi.org/10.1074/jbc.M601174200.
43. Delaglio F, Grzesiek S, Vuister GW, Zhu G, Pfeifer J, Bax A. 1995. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR 6:277-293.
44. Nguyen HT, Sheu TG, Mishin VP, Klimov AI, Gubareva LV. 2010. Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. Antimicrob. Agents Chemother. 54:3671-3677. http://dx.doi.org/10.1128/AAC.00581-10.
45. Nguyen JT, Hoopes JD, Le MH, Smee DF, Patick AK, Faix DJ, Blair PJ, de Jong MD, Prichard MN, Went GT. 2010. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS One 5:e9332. http://dx.doi.org/10.1371/journal.pone.0009332.
46. Nguyen JT, Hoopes JD, Smee DF, Prichard MN, Driebe EM, Engelthaler DM, Le MH, Keim PS, Spence RP, Went GT. 2009. Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro. Antimicrob. Agents Chemother. 53:4115-4126. http://dx.doi.org/10.1128/AAC.00476-09.
47. Prichard MN, Prichard LE, Shipman C, Jr. 1993. Strategic design and three-dimensional analysis of antiviral drug combinations. Antimicrob. Agents Chemother. 37:540-545. http://dx.doi.org/10.1128/AAC.37.3.540.
48. Prichard MN, Shipman C, Jr. 1990. A three-dimensional model to analyze drug-drug interactions. Antiviral Res. 14:181-205. http://dx.doi.org/10.1016/0166-3542(90)90001-N.
49. Wang SY, Su CY, Lin M, Huang SY, Huang WI, Wang CC, Wu YT, Cheng TJ, Yu HM, Ren CT, Wu CY, Wong CH, Cheng YS. 2009. HA-pseudotyped retroviral vectors for influenza antagonist screening. J. Biomol. Screen. 14: 294-302. http://dx.doi.org/10.1177/1087057108330786.
50. Sakabe S, Iwatsuki-Horimoto K, Horimoto T, Nidom CA, Le M, Takano R, Kubota-Koketsu R, Okuno Y, Ozawa M, Kawaoka Y. 2010. A cross-reactive neutralizing monoclonal antibody protects mice from H5N1 and pandemic (H1N1) 2009 virus infection. Antiviral Res. 88:249-255. http://dx.doi.org/10.1016/j.antiviral.2010.09.007.
51. Corti D, Lanzavecchia A. 2013. Broadly neutralizing antiviral antibodies. Annu. Rev. Immunol. 31:705-742. http://dx.doi.org/10.1146/annurev-immunol-032712-095916.
52. Corti D, Suguitan AL, Jr, Pinna D, Silacci C, Fernandez-Rodriguez BM, Vanzetta F, Santos C, Luke CJ, Torres-Velez FJ, Temperton NJ, Weiss RA, Sallusto F, Subbarao K, Lanzavecchia A. 2010. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J. Clin. Invest. 120:1663-1673. http://dx.doi .org/10.1172/JCI41902.
53. Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M, Throsby M, Goudsmit J, Wilson IA. 2009. Antibody recognition of a highly conserved influenza virus epitope. Science 324:246-251. http://dx.doi.org/10.1126/science.1171491.
54. Nabel GJ, Fauci AS. 2010. Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine. Nat. Med. 16:1389-1391. http://dx.doi.org/10.1038/nm1210-1389.
55. Wei CJ, Boyington JC, McTamney PM, Kong WP, Pearce MB, Xu L, Andersen H, Rao S, Tumpey TM, Yang ZY, Nabel GJ. 2010. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 329:1060-1064. http://dx.doi.org/10.1126/science.1192517.
56. Dreyfus C, Ekiert DC, Wilson IA. 2013. Structure of a classical broadly neutralizing stem antibody in complex with a pandemic H2 influenza virus hemagglutinin. J. Virol. 87:7149-7154. http://dx.doi.org/10.1128/JVI.02975-12.
57. Sui J, Sheehan J, Hwang WC, Bankston LA, Burchett SK, Huang CY, Liddington RC, Beigel JH, Marasco WA. 2011. Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza A antibodies. Clin. Infect. Dis. 52:1003-1009. http://dx.doi.org/10.1093/cid/cir121.
58. Leneva IA, Russell RJ, Boriskin YS, Hay AJ. 2009. Characteristics of arbidol-resistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol. Antiviral Res. 81:132-140. http://dx.doi.org/10.1016/j.antiviral.2008.10.009.
59. Russell RJ, Gamblin SJ, Haire LF, Stevens DJ, Xiao B, Ha Y, Skehel JJ. 2004. H1 and H7 influenza haemagglutinin structures extend a structural classification of haemagglutinin subtypes. Virology 325:287-296. http://dx.doi.org/10.1016/j.virol.2004.04.040.
60. Russell RJ, Kerry PS, Stevens DJ, Steinhauer DA, Martin SR, Gamblin SJ, Skehel JJ. 2008. Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion. Proc. Natl. Acad. Sci. U.S.A. 105: 17736-17741. http://dx.doi.org/10.1073/pnas.0807142105.
61. Staschke KA, Hatch SD, Tang JC, Hornback WJ, Munroe JE, Colacino JM, Muesing MA. 1998. Inhibition of influenza virus hemagglutininmediated membrane fusion by a compound related to podocarpic acid. Virology 248:264-274. http://dx.doi.org/10.1006/viro.1998.9273.
62. Yoshimoto J, Kakui M, Iwasaki H, Fujiwara T, Sugimoto H, Hattori N. 1999. Identification of a novel HA conformational change inhibitor of human influenza virus. Arch. Virol. 144:865-878. http://dx.doi.org/10 .1007/s007050050552.
63. Yoshimoto J, Kakui M, Iwasaki H, Sugimoto H, Fujiwara T, Hattori N. 2000. Identification of amino acids of influenza virus HA responsible for resistance to a fusion inhibitor, stachyflin. Microbiol. Immunol. 44:677-685. http://dx.doi.org/10.1111/j.1348-0421.2000.tb02549.x.